With the recent approval of Nivolumab + Ipilimumab in MSI-H Colorectal cancer, how do you decide between this combination and Pembrolizumab?  

The data are fairly clear that patients with the combination of nivolumab and ipilimumab is highly active based on the Checkmate-142 study (Overman, et al, JCO 36, no. 8 (March 10 2018): 773-779, 2018) showing a 55% RR with 5% CR (n=119 patients, all post at least 2 prior chemo regimens). ...